Ovarian hormones are not required for PRL-induced mammary tumorigenesis, but estrogen enhances neoplastic processes

Journal of Endocrinology

Volumn 203, Issue 1, 2009, Pages 99-110

  Arendt, Lisa M ^a,c   Evans, Lindsay C ^a   Rugowski, Debra E ^a   Garcia Barchino, Maria Jose ^b,d   Rui, Hallgeir ^b   Schuler, Linda A ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR ALPHA; LIPOCALIN; MASPIN; MITOGEN ACTIVATED PROTEIN KINASE 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OVARY PEPTIDE HORMONE; PROLACTIN; PROTEIN KINASE B; STAT5 PROTEIN; TENASCIN; ESTRADIOL;

AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CANCER INVASION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; LATENT PERIOD; MOUSE; MYOEPITHELIUM CELL; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RISK FACTOR; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANIMAL; EXPERIMENTAL NEOPLASM; GENE EXPRESSION; METABOLISM; ONCOGENESIS AND MALIGNANT TRANSFORMATION; PHYSIOLOGY; PRECANCER; TRANSGENIC MOUSE; UDDER;

AGING; ANIMALS; CELL PROLIFERATION; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; GENE EXPRESSION; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; NEOPLASTIC PROCESSES; PRECANCEROUS CONDITIONS; PROLACTIN; SIGNAL TRANSDUCTION;

EID: 70349758953     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1677/JOE-09-0221     Document Type: Article

References (79)

1. Adriance MC, Inman JL, Petersen OW& Bissell MJ 2005 Myoepithelial cells: good fences make good neighbors. Breast Cancer Research 7 190-197.
2. Alarid ET 2006 Lives and times of nuclear receptors. Molecular Endocrinology 20 1972-1981.
3. Anderson E, Clarke RB & Howell A 2000 Estrogen receptor in mammary gland physiology. In Contemporary Endocrinology: Endocrine Oncology, pp 1-16. Ed. SP Ethier. Totowa, NJ: Humana Press, Inc.
4. Arendt LM & Schuler LA 2008 Transgenic models to study actions of prolactin in mammary neoplasia. Journal of Mammary Gland Biology and Neoplasia 13 29-40.
5. Arendt LM, Rose-Hellekant TA, Sandgren EP & Schuler LA 2006 Prolactin potentiates TGFα induction of mammary neoplasia in transgenic mice. American Journal of Pathology 168 1365-1374.
6. Arendt LM, Grafwallner-Huseth TL & Schuler LA 2009 Prolactin-growth factor crosstalk reduces mammary estrogen responsiveness despite elevated ERα expression. American Journal of Pathology 174 1065-1074.
7. Asselin-Labat ML, Shackleton M, Stingl J, Vaillant F, Forrest NC, Eaves CJ, Visvader JE & Lindeman GJ 2006 Steroid hormone receptor status of mouse mammary stem cells. Journal of the National Cancer Institute 98 1011-1014. (Pubitemid 44288166)
8. Bailey CM, Khalkhali-Ellis Z, Seftor EA & Hendrix MJ 2006 Biological functions of maspin. Journal of Cellular Physiology 209 617-624.
9. Barsky SH & Karlin NJ 2005 Myoepithelial cells: autocrine and paracrine suppressors of breast cancer progression. Journal of Mammary Gland Biology and Neoplasia 10 249-260.
10. Bera TK, Hwang S, Swanson SM, Guzman RC, Edery M & Nandi S 1994 In situ localization of prolactin receptor message in the mammary glands of pituitary-isografted mice. Molecular and Cellular Biochemistry 132 145-149.
11. Bieche I, Girault I, Sabourin JC, Tozlu S, Driouch K, Vidaud M& Lidereau R 2003 Prognostic value of maspin mRNA expression in ER alpha-positive postmenopausal breast carcinomas. British Journal of Cancer 88 863-870. (Pubitemid 36520873)
12. Booth BW & Smith GH 2006 Estrogen receptor-alpha and progesterone receptor are expressed in label-retaining mammary epithelial cells that divide asymmetrically and retain their template DNA strands. Breast Cancer Research 8 R49.
13. Brisken C, Ayyannan A, Nguyen C, Heineman A, Reinhardt F, Tan J, Dey SK, Dotto GP & Weinberg RA 2002 IGF-2 is a mediator of prolactin-induced morphogenesis in the breast. Developmental Cell 3 877-887. (Pubitemid 35460787)
14. Calvo A, Catena R, Noble MS, Carbott D, Gil-Bazo I, Gonzalez-Moreno O, Huh JI, Sharp R, Qiu TH, Anver MR et al. 2008 Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis. Oncogene 27 5373-5384.
15. Carver KC & Schuler LA 2008 Prolactin does not require insulin-like growth factor (IGF) intermediates, but synergizes with IGF-1 in human breast cancer cells. Molecular Cancer Research 6 634-643.
16. Clarke RB, Howell A, Potten CS & Anderson E 1997 Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Research 57 4987-4991. (Pubitemid 27498105)
17. Clevenger CV, Furth PA, Hankinson SE & Schuler LA 2003 Role of prolactin in mammary carcinoma. Endocrine Reviews 24 1-27.
18. Dillon RL, White DE & Muller WJ 2007 The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 26 1338-1345.
19. Edery M, Imagawa W, Larson L & Nandi S 1985 Regulation of estrogen and progesterone receptor levels in mouse mammary epithelial cells grown in serum-free collagen gel cultures. Endocrinology 116 105-112. (Pubitemid 15190455)
20. Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M& Hankinson SE 2006 Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. Journal of the National Cancer Institute 98 1406-1415. (Pubitemid 44530717)
21. Faraldo MM, Teuliere J, Deugnier MA, Taddei-De La Hosseraye I, Thiery JP & Glukhova MA 2005 Myoepithelial cells in the control of mammary development and tumorigenesis: data from genetically modified mice. Journal of Mammary Gland Biology and Neoplasia 10 211-219.
22. Frasor J & Gibori G 2003 Prolactin regulation of estrogen receptor expression. Trends in Endocrinology and Metabolism 14 118-123. (Pubitemid 36733909)
23. Ginsburg E & Vonderhaar BK 1995 Prolactin synthesis and secretion by human breast cancer cells. Cancer Research 55 2591-2595.
24. Goffin V, Binart N, Touraine P & Kelly PA 2002 Prolactin: the new biology of an old hormone. Annual Review of Physiology 64 47-67. (Pubitemid 34259225)
25. Grimm SL, Seagroves TN, Kabotyanski EB, Hovey RC, Vonderhaar BK, Lydon JP, Miyoshi K, Hennighausen L, Ormandy CJ, Lee AV et al. 2002 Disruption of steroid and prolactin receptor patterning in the mammary gland correlates with a block in lobuloalveolar development. Molecular Endocrinology 16 2675-2691. (Pubitemid 36020650)
26. Gudjonsson T, Ronnov-Jessen L, Villadsen R, Rank F, Bissell MJ & Petersen OW 2002 Normal and tumor-derived myoepithelial cells differ in their ability to interact with luminal breast epithelial cells for polarity and basement membrane deposition. Journal of Cell Science 115 39-50. (Pubitemid 34105527)
27. Gudjonsson T, Adriance MC, Sternlicht MD, Petersen OW & Bissell MJ 2005 Myoepithelial cells: their origin and function in breast morphogenesis and neoplasia. Journal of Mammary Gland Biology and Neoplasia 10 261-272.
28. Gupta PB, Proia D, Cingoz O, Weremowicz J, Naber SP, Weinberg RA & Kuperwasser C 2007 Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. Cancer Research 67 2062-2071. (Pubitemid 46424224)
29. Gutzman JH, Miller KK & Schuler LA 2004a Endogenous hPRL and not exogenous hPRL induces ERα and PRLR expression and increases estrogen responsiveness in breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology 88 69-77.
30. Gutzman JH, Rugowski DE, Schroeder MD, Watters JJ & Schuler LA 2004b Multiple kinase cascades mediate prolactin signals to activating protein-1 in breast cancer cells. Molecular Endocrinology 18 3064-3075.
31. Gutzman JH, Nikolai SE, Rugowski DE, Watters JJ & Schuler LA 2005 Prolactin and estrogen enhance the activity of activating protein-1 in breast cancer cells: role of ERK1/2-mediated signals to c-fos. Molecular Endocrinology 19 1765-1778.
32. Gutzman JH, Rugowski DE, Nikolai SE & Schuler LA 2007 Stat5 activation inhibits prolactin-induced AP-1 activity: distinct prolactin initiated signals in tumorigenesis dependent on cell context. Oncogene 26 6341-6348.
33. Haslam SZ & Woodward TL 2003 Host microenvironment in breast cancer development: epithelial-cell-stromal-cell interactions and steroid hormone action in normal and cancerous mammary gland. Breast Cancer Research 5 208-215.
34. Hovey RC, Trott JF, Ginsburg E, Goldhar A, Sasaki MM, Fountain SJ, Sundararajan K & Vonderhaar BK 2001 Transcriptional and spatiotemporal regulation of prolactin receptor mRNA and cooperativity with progesterone receptor function during ductal branch growth in the mammary gland. Developmental Dynamics 222 192-205. (Pubitemid 32938481)
35. Hovey RC, Harris J, Hadsell DL, Lee AV, Ormandy CJ & Vonderhaar BK 2003 Local insulin-like growth factor-II mediates prolactin-induced mammary gland development. Molecular Endocrinology 17 460-471. (Pubitemid 36315639)
36. Huang Y, Li X, Jiang J & Frank SJ 2006 Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells. Oncogene 25 7565-7576. (Pubitemid 44924470)
37. Jones PL 2001 Extracellular matrix and tenascin-C in pathogenesis of breast cancer. Lancet 357 1992-1994. (Pubitemid 32592382)
38. Kenny PA & Bissell MJ 2003 Tumor reversion: correction of malignant behavior by microenvironmental cues. International Journal of Cancer 107 688-695.
39. Liu W, Bagaitkar J & Watabe K 2007 Roles of AKT signal in breast cancer. Frontiers of Bioscience 12 4011-4019.
40. Maatta M, Virtanen I, Burgeson R & Autio-Harmainen H 2001 Comparative analysis of the distribution of laminin chains in the basement membranes in some malignant epithelial tumors: the alpha1 chain of laminin shows a selected expression pattern in human carcinomas. Journal of Histochemistry and Cytochemistry 49 711-726. (Pubitemid 32553442)
41. Manhes C, Kayser C, Bertheau P, Kelder B, Kopchick JJ, Kelly PA, Touraine P & Goffin V 2006 Local over-expression of prolactin in differentiating mouse mammary gland induces functional defects and benign lesions, but no carcinoma. Journal of Endocrinology 190 271-285. (Pubitemid 44288365)
42. McHale K, Tomaszewski JE, Puthiyaveettil R, Livolsi VA & Clevenger CV 2008 Altered expression of prolactin receptor-associated signaling proteins in human breast carcinoma. Modern Pathology 21 565-571. (Pubitemid 351589663)
43. Medina D, Kittrell FS, Shepard A, Contreras A, Rosen JM & Lydon J 2003 Hormone dependence in premalignant mammary progression. Cancer Research 63 1067-1072. (Pubitemid 36278440)
44. Milde-Langosch K, Bamberger AM, Rieck G, Grund D, Hemminger G, Muller V & Loning T 2005 Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer. British Journal of Cancer 92 2206-2215. (Pubitemid 40966259)
45. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL & Massague J 2005 Genes that mediate breast cancer metastasis to lung. Nature 436 518-524. (Pubitemid 41112921)
46. Mueller SO, Clark JA, Myers PH & Korach KS 2002 Mammary gland development in adult mice requires epithelial and stromal estrogen receptor α. Endocrinology 143 2357-2365.
47. Nakano S, Iyama K, Ogawa M, Yoshioka H, Sado Y, Oohashi T & Ninomiya Y 1999 Differential tissular expression and localization of type IV collagen alpha1(IV), alpha2(IV), alpha5(IV), and alpha6(IV) chains and their mRNA in normal breast and in benign and malignant breast tumors. Laboratory Investigation 79 281-292. (Pubitemid 29166443)
48. Nandi S, Guzman RC & Yang J 1995 Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. PNAS 92 3650-3657.
49. Naylor MJ, Li N, Cheung J, Lowe ET, Lambert E, Marlow R, Wang P, Schatzmann F, Wintermantel T, Schuetz G et al. 2005 Ablation of beta1 integrin in mammary epithelium reveals a key role for integrin in glandular morphogenesis and differentiation. Journal of Cellular Biology 171 717-728. (Pubitemid 41668730)
50. Nevalainen MT, Xie JW, Bubendorf L, Wagner KU & Rui H 2002 Basal activation of transcription factor Stat5 in nonpregnant mouse and human breast epithelium. Molecular Endocrinology 16 1108-1124.
51. Novaro V, Roskelley CD & Bissell MJ 2003 Collagen-IV and laminin-1 regulate estrogen receptor α expression and function in mouse mammary epithelial cells. Journal of Cell Science 116 2975-2986. (Pubitemid 36926986)
52. Oakes SR, Robertson FG, Kench JG, Gardiner-Garden M, Wand MP, Green JE & Ormandy CJ 2007 Loss of mammary epithelial prolactin receptor delays tumor formation by reducing cell proliferation in low-grade preinvasive lesions. Oncogene 26 543-553. (Pubitemid 46160968)
53. Orend G & Chiquet-Ehrismann R 2006 Tenascin-C induced signaling in cancer. Cancer Letters 244 143-163.
54. Pearse G, Frith J, Randall KJ & Klinowska T 2009 Urinary retention and cystitis associated with subcutaneous estradiol pellets in female nude mice. Toxicologic Pathology 37 227-234.
55. Polyak K & Hu M 2005 Do myoepithelial cells hold the key for breast tumor progression? Journal of Mammary Gland Biology and Neoplasia 10 231-247.
56. Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP & Schuler LA 2003 Prolactin induces ERα-positive and ERα-negative mammary cancer in transgenic mice. Oncogene 22 4664-4674. (Pubitemid 36976441)
57. Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH & Yue W 2002 The role of mitogen-activated protein (MAP) kinase in breast cancer. Journal of Steroid Biochemistry and Molecular Biology 80 239-256. (Pubitemid 34233743)
58. Santos SJ, Haslam SZ & Conrad SE 2008 Estrogen and progesterone are critical regulators of Stat5a expression in the mouse mammary gland. Endocrinology 149 329-338.
59. Sebolt-Leopold JS & Herrera R 2004 Targeting the mitogen-activated protein kinase cascade to treat cancer. Nature Reviews. Cancer 4 937-947. (Pubitemid 39626217)
60. Shimkin MB 1948 Breast cancer in mice. California Medicine 68 264-269.
61. Shoker BS, Jarvis C, Clarke RB, Anderson E, Hewlett J, Davies MP, Sibson DR & Sloane JP 1999 Estrogen receptor-positive proliferating cells in the normal and precancerous breast. American Journal of Pathology 155 1811-1815.
62. Shyamala G, Chou YC, Louie SG, Guzman RC, Smith GH & Nandi S 2002 Cellular expression of estrogen and progesterone receptors in mammary glands: regulation by hormones, development and aging. Journal of Steroid Biochemistry and Molecular Biology 80 137-148. (Pubitemid 34233736)
63. Silva CM & Shupnik MA 2007 Integration of steroid and growth factor pathways in breast cancer: focus on signal transducers and activators of transcription and their potential role in resistance. Molecular Endocrinology 21 1499-1512.
64. Sleeman KE, Kendrick H, Robertson D, Isacke CM, Ashworth A & Smalley MJ 2007 Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland. Journal of Cell Biology 176 19-26. (Pubitemid 46041676)
65. Smith GH & Chepko G 2001 Mammary epithelial stem cells. Microscopy Research and Technique 52 190-203.
66. Smith CA, Monaghan P & Neville AM 1984 Basal clear cells of the normal human breast. Virchows Archiv. A, Pathological Anatomy and Histopathology 402 319-329.
67. Suriano R, Chaudhuri D, Johnson RS, Lambers E, Ashok BT, Kishore R & Tiwari RK 2008 17betta-estradiol mobilizes bone marrow-derived endothelial progenitor cells to tumors. Cancer Research 68 6038-6042.
68. Svensson S, Jirstrom K, Ryden L, Roos G, Emdin S, Ostrowski MC & Landberg G 2005 ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis. Oncogene 24 (Pubitemid 40961760) 4370-4379.
69. Tam SP, Lau P, Djiane J, Hilton DJ & Waters MJ 2001 Tissue-specific induction of SOCS gene expression by PRL. Endocrinology 142 5015-5026. (Pubitemid 33022378)
70. The Endogenous Hormones and Breast Cancer Collaborative Group 2002 Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. Journal of the National Cancer Institute 94 606-616.
71. Tsoli E, Tsantoulis PK, Papalambros A, Perunovic B, England D, Rawlands DA, Reynolds GM, Vlachodimitropoulos D, Morgan SL, Spiliopoulou CA et al. 2007 Simultaneous evaluation of maspin and CXCR4 in patients with breast cancer. Journal of Clinical Pathology 60 261-266. (Pubitemid 46447740)
72. Turley EA, Veiseh M, Radisky DC & Bissell MJ 2008 Mechanisms of disease: epithelial-mesenchymal transition - does cellular plasticity fuel neoplastic progression? Nature Clinical Practice. Oncology 5 280-290. (Pubitemid 351594144)
73. Tworoger SS & Hankinson SE 2006 Prolactin and breast cancer risk. Cancer Letters 243 160-169.
74. Tworoger SS & Hankinson SE 2008 Prolactin and breast cancer etiology: an epidemiologic perspective. Journal of Mammary Gland Biology and Neoplasia 13 41-53.
75. Vivanco I & Sawyers CL 2002 The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nature Reviews. Cancer 2 489-501. (Pubitemid 37328931)
76. Wagner KU & Rui H 2008 Jak2/Stat5 signaling in mammogenesis, breast cancer initiation and progression. Journal of Mammary Gland Biology and Neoplasia 13 93-103.
77. Writing Group for the Women's Health Initiative Investigators 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principle results from the women's health initiative randomized controlled trial. Journal of the American Medical Association 288 321-333.
78. Yoshidome K, Shibata MA, Couldrey C, Korach KS & Green JE 2000 Estrogen promotes mammary tumor development in C3(1)/SV40 large T-antigen transgenic mice: paradoxical loss of estrogen receptor alpha expression during tumor progression. Cancer Research 60 6901-6910. (Pubitemid 32059162)
79. Zinger M, McFarland M & Ben Jonathan N 2003 Prolactin expression and secretion by human breast glandular and adipose tissue explants. Journal of Clinical Endocrinology and Metabolism 88 689-696. (Pubitemid 36207809)